Research & Literature

Extranodal NK/T cell lymphoma and aggressive NK cell leukaemia: evidence for their origin on CD56+bright CD16-/+dim NK cells.

Lima M

Pathology 2015; (47(6)):503-14 doi:10.1097/PAT.0000000000000275.

Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.

Wang L, Wang H, Wang JH, et al.

Oncotarget 2015; (6(30)):30317-26 doi:10.18632/oncotarget.4505.

Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.

Oh D, Ahn YC, Kim SJ, et al.

International journal of radiation oncology, biology, physics 2015; (93(3)):677-83.

ATP-binding cassette sub-family C member 4 (ABCC4) is overexpressed in human NK/T-cell lymphoma and regulates chemotherapy sensitivity: Potential as a functional therapeutic target.

Zhang X, Zhao L, Li X, et al.

Leukemia research 2015; (39(12)):1448-54.

Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis.

Kim SJ, Choi JY, Hyun SH, et al.

The Lancet. Haematology 2015; (2(2)):e66-74.

A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.

Kim SJ, Yoon DH, Jaccard A, et al.

The Lancet. Oncology 2016; (17(3)):389-400 doi:10.1016/S1470-2045(15)00533-1.

DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China.

Li X, Cui Y, Sun Z, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2016; (22(21)):5223-5228 doi:10.1158/1078-0432.CCR-16-0153.

Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.

Wang JH, Wang L, Liu CC, et al.

Oncotarget 2016; (7(20)):29092-101 doi:10.18632/oncotarget.8647.

A case of primary pulmonary NK/T cell lymphoma presenting as pneumonia.

Lee S, Shin B, Yoon H, et al.

Respiratory medicine case reports 2016; (17()):1-4 doi:10.1016/j.rmcr.2015.11.003.

Diagnosis and management of extranodal NK/T cell lymphoma nasal type.

Tse E, Kwong YL

Expert review of hematology 2016; (9(9)):861-71 doi:10.1080/17474086.2016.1206465.

Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma.

Yang CW, Wang CW, Hong RL, et al.

Journal of radiation research 2017; (58(1)):114-122 doi:10.1093/jrr/rrw081.

Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).

Yoon DH, Kim SJ, Jeong SH, et al.

Oncotarget 2016; (7(51)):85584-85591 doi:10.18632/oncotarget.11319.

Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.

Haverkos BM, Pan Z, Gru AA, et al.

Current hematologic malignancy reports 2016; (11(6)):514-527 doi:10.1007/s11899-016-0355-9.

A neutralized human LMP1-IgG inhibits ENKTL growth by suppressing the JAK3/STAT3 signaling pathway.

Mao Y, Wang J, Zhang M, et al.

Oncotarget 2017; (8(7)):10954-10965 doi:10.18632/oncotarget.14032.

The diagnosis and management of NK/T-cell lymphomas.

Tse E, Kwong YL

Journal of hematology & oncology 2017; (10(1)):85 doi:10.1186/s13045-017-0452-9.

Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL).

Haverkos BM, Coleman C, Gru AA, et al.

Discovery medicine 2017; (23(126)):189-199.

Deceptive nasal NK/T-cell lymphoma.

Thakur JS, Mahajan A, Saluja M, Mohindroo NK

Tropical doctor 2017; (47(3)):268-271 doi:10.1177/0049475516684088.

NK/T Cell Lymphoma: Updates in Therapy.

Suzuki R

Current hematologic malignancy reports 2018; (13(1)):7-12 doi:10.1007/s11899-018-0430-5.

Late diagnosis: a case of rapidly progressive extranodal NK/T cell lymphoma, nasal type.

Mori H, Ebisawa K, Nishimura M, Kanazawa K

BMJ case reports 2018; (2018()) doi:10.1136/bcr-2017-221019.

Prognostic significance of Epstein-Barr virus DNA in NK/T-cell lymphoma: a meta-analysis.

Fei Q, Tian XK, Wu J, et al.

OncoTargets and therapy 2018; (11()):997-1004 doi:10.2147/OTT.S153942.

Natural Killer/T-cell Neoplasms: Analysis of Incidence, Patient Characteristics, and Survival Outcomes in the United States.

Kommalapati A, Tella SH, Ganti AK, Armitage JO

Clinical lymphoma, myeloma & leukemia 2018; (18(7)):475-479 doi:10.1016/j.clml.2018.04.009.

[Extranodal NK/T-cell lymphoma, nasal type: a clinical analysis].

Chen F, Shen CX, Wang HG, et al.

Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery 2017; (31(5)):327-333 doi:10.13201/j.issn.1001-1781.2017.05.001.

Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?

Zhang X, Fu X, Dong M, et al.

Cancer cell international 2018; (18()):150 doi:10.1186/s12935-018-0644-6.

The Clinical Utility of Circulating Epstein-Barr Virus DNA Concentrations in NK/T-Cell Lymphoma: A Meta-Analysis.

Liu ZL, Bi XW, Liu PP, et al.

Disease markers 2018; (2018()):1961058 doi:10.1155/2018/1961058.

Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol.

Wang XX, Li PF, Bai B, et al.

Leukemia & lymphoma 2019; (60(8)):1917-1925 doi:10.1080/10428194.2018.1563690.

Transcriptomic Abnormalities in Epstein Barr Virus Associated T/NK Lymphoproliferative Disorders.

de Mel S, Tan JZ, Jeyasekharan AD, et al.

Frontiers in pediatrics 2018; (6()):405 doi:10.3389/fped.2018.00405.

JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-9. Extranodal NK/T-cell lymphoma, nasal type (ENKL).

Yamaguchi M, Suzuki R

International journal of hematology 2019; (109(4)):371-376 doi:10.1007/s12185-019-02609-x.

Laryngeal Extranodal Nasal-type Natural Killer/T-cell Lymphoma: A Clinicopathologic Study of 31 Cases in China.

Xiang CX, Chen ZH, Zhao S, et al.

The American journal of surgical pathology 2019; (43(7)):995-1004 doi:10.1097/PAS.0000000000001266.

Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III-IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus.

Zhao Q, Fan S, Chang Y, et al.

Cancer management and research 2019; (11()):3555-3564 doi:10.2147/CMAR.S191929.

Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas.

Tse E, Au-Yeung R, Kwong YL

Expert review of hematology 2019; (12(11)):927-935 doi:10.1080/17474086.2019.1660640.

Case of Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Presenting With Intravascular Localization of Tumor Cells in Skin Biopsies From Both Plaque and Normal-Appearing Skin: A Case Report and Literature Review.

Obara K, Amoh Y

The American Journal of dermatopathology 2020; (42(3)):196-203 doi:10.1097/DAD.0000000000001523.

Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making.

Chen SY, Yang Y, Qi SN, et al.

Leukemia 2021; (35(1)):130-142 doi:10.1038/s41375-020-0791-3.

[Survival and Prognosis of Patients with Nasal NK/T-Cell Lymphoma].

Xie DN, Li YH, Chen XJ, et al.

Zhongguo shi yan xue ye xue za zhi 2020; (28(2)):507-511 doi:10.19746/j.cnki.issn.1009-2137.2020.02.025.

Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study.

Wang H, Wang L, Li C, et al.

The oncologist 2020; (25(11)):e1725-e1731 doi:10.1634/theoncologist.2020-0144.

Natural Killer (NK)//T-Cell Lymphoma, Nasal Type, with Periorbital Involvement: A Case Report and Literature Review.

Lisowska G, Zięba N, Stryjewska-Makuch G, et al.

The American journal of case reports 2020; (21()):e926599 doi:10.12659/AJCR.926599.

[Clinical characteristics and survival analysis of primary intestinal extranodal NK/T-cell lymphoma, nasal type].

Li Y, Wang XJ, Li YN, et al.

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2020; (41(10)):818-821 doi:10.3760/cma.j.issn.0253-2727.2020.10.005.

Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment.

van Doesum JA, Niezink AGH, Huls GA, et al.

HemaSphere 2021; (5(2)):e523 doi:10.1097/HS9.0000000000000523.

Diagnostic approach to T- and NK-cell lymphoproliferative disorders in the gastrointestinal tract.

Susan SH, Ng SB, Wang S, Tan SY

Seminars in diagnostic pathology 2021; (38(4)):21-30 doi:10.1053/j.semdp.2021.03.004.

Clinical Significance of Plasma Epstein-Barr Virus DNA in Peripheral T-Cell Lymphomas.

Zhao D, Hu S, Zhou D, et al.

Acta haematologica 2022; (145(2)):132-143 doi:10.1159/000516588.

Extranodal natural killer/T-cell lymphoma of the breast: a retrospective clinicopathological analysis of a consecutive 11-year case series.

Liu W, Chen Z, Li F, et al.

Orphanet journal of rare diseases 2021; (16(1)):479 doi:10.1186/s13023-021-02110-x.

Peripheral T cell lymphoma of the nasopharynx with expansion of EBV-positive B cells masquerading as an extranodal NK/T cell lymphoma, nasal type.

Kim HN, Kim DS, Jeon MJ, et al.

Virchows Archiv : an international journal of pathology 2022; (481(1)):125-129 doi:10.1007/s00428-021-03240-0.

The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma.

Kim H, Ko YH

Life (Basel, Switzerland) 2022; (12(1)) doi:10.3390/life12010073.

New Approaches for Treatment of Advanced Extranodal NK/T-Cell Lymphoma.

Yi W, Yang T, Lin S, et al.

Cancer management and research 2022; (14()):401-407 doi:10.2147/CMAR.S328846.

EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management.

Malpica L, Marques-Piubelli ML, Beltran BE, et al.

American journal of hematology 2022; (97(7)):951-965 doi:10.1002/ajh.26579.

Evaluation of different staging systems and prognostic analysis of nasal-type extranodal NK/T-cell lymphoma based on consistent LVDP chemotherapy regimen.

Wu W, Ren K, Li N, et al.

Translational oncology 2022; (21()):101437 doi:10.1016/j.tranon.2022.101437.

How we treat NK/T-cell lymphomas.

Tse E, Zhao WL, Xiong J, Kwong YL

Journal of hematology & oncology 2022; (15(1)):74 doi:10.1186/s13045-022-01293-5.

PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas.

Xie W, Medeiros LJ, Li S, et al.

Biomedicines 2022; (10(7)) doi:10.3390/biomedicines10071587.

Primary small intestinal extranodal NK/T cell lymphoma, nasal type with kidney involvement: a rare case report and literature review.

Mao S, Diao C, Cao L

Diagnostic pathology 2022; (17(1)):75 doi:10.1186/s13000-022-01254-z.

Efficacy and safety of PD-1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective study.

Tian J, Hao M, Liu Q, et al.

Hematological oncology 2023; (41(3)):396-406 doi:10.1002/hon.3116.

Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T-cell lymphoma: A French retrospective study.

Chaubard S, Marouf A, Lavergne D, et al.

British journal of haematology 2023; (201(4)):673-681 doi:10.1111/bjh.18689.

Primary Breast Natural Killer/T-cell lymphoma with Cutaneous Involvement: A Case Report.

Wu H, Jin SY

Alternative therapies in health and medicine 2023; (29(8)):252-254.

Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports.

Rivera-Francia VM, Failoc-Rojas VE, Villacorta-Carranza R, et al.

Leukemia & lymphoma 2024; (65(1)):37-47 doi:10.1080/10428194.2023.2264431.

Appropriate timing to perform an interim 18F-FDG PET/CT in patients with nasal-type extranodal natural killer/T cell lymphoma.

Wang R, Zhang Y, Fan Q, et al.

Annals of hematology 2024; (103(3)):885-892 doi:10.1007/s00277-023-05562-2.

Disseminated Nasal subtype Extranodal NK/T-cell lymphoma and its diagnostic difficulties in antemortem biopsies.

Sekar A, Jain S, Bakshi J, et al.

Autopsy & case reports 2023; (13()):e2023445 doi:10.4322/acr.2023.445.

Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma.

Chen Z, Huang H, Huang H, et al.

Leukemia 2024; (38(4)):829-839 doi:10.1038/s41375-024-02171-4.

Extranodal NK/T-cell lymphoma with localized relapse in bone marrow of lower leg detected using PET-CT.

Nakamura T, Tatetsu H, Higuchi Y, et al.

Journal of clinical and experimental hematopathology : JCEH 2024; (64(1)):45-51 doi:10.3960/jslrt.23046.

Extranodal natural killer/T-cell lymphoma coexisting with peripheral T-cell lymphoma, not otherwise specified.

Hayashino K, Yoshida C, Ayata Y, et al.

Journal of clinical and experimental hematopathology : JCEH 2024; (64(1)):52-58 doi:10.3960/jslrt.23049.

Association between Epstein-Barr virus LMP-1 and Hodgkin lymphoma LMP-1 mechanisms in Hodgkin lymphoma development.

Oliveira LOD, Costa IB, Quaresma JAS

Reviews in medical virology 2024; (34(4)):e2561 doi:10.1002/rmv.2561.

Primary Testicular Extranodal NK/T-cell Lymphoma Nasal Type Associated With Epstein-Barr Virus Infection: A Moroccan Case Report.

Nejjari H, Ait Zine I, Ammouri W, et al.

Cureus 2024; (16(6)):e63361 doi:10.7759/cureus.63361.

[Clinical features and prognostic analysis of colorectal extranodal NK/T cell lymphoma].

Li XY, Yao JN, Dong XY, et al.

Zhonghua zhong liu za zhi [Chinese journal of oncology] 2024; (46(8)):782-793 doi:10.3760/cma.j.cn112152-20231026-00260.

Quality of life in disease-free survived patients with early-stage extranodal nasal-type NK/T-cell lymphoma after definitive intensity-modulated radiotherapy: a cross-sectional study of 310 cases.

Li YY, Li YM, Niu SQ, et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2024; (32(11)):727 doi:10.1007/s00520-024-08932-2.

An evaluation of sugemalimab for the treatment of relapsed or refractory extranodal natural killer T-cell lymphoma.

Feng Y, Liu X, Yu J, et al.

Expert opinion on biological therapy 2025; (25(1)):9-14 doi:10.1080/14712598.2024.2444400.

Clinical Manifestations, Prognostic Factors, and Outcomes of Extranodal Natural Killer T-Cell Lymphoma: A Single-Center Experience in Thailand.

Kaewboot W, Norasetthada L, Tantiworawit A, et al.

Hematology reports 2024; (16(4)):769-780 doi:10.3390/hematolrep16040073.

Primary Intestinal NK/T-cell Lymphoma Masquerading as Crohn's Disease: A Report of Two Cases.

Jayakumar P, Singh L, Ahuja V, et al.

Cureus 2025; (17(1)):e77056 doi:10.7759/cureus.77056.

Prognostic impact of pre-treatment and post-treatment plasma Epstein-Barr virus DNA in peripheral T-cell lymphomas.

Chan CY, Lin TL, Kuo MC, et al.

Annals of medicine 2025; (57(1)):2478315 doi:10.1080/07853890.2025.2478315.

The role of 18F-FDG PET/CT in diagnosing cardiac infiltration and therapeutic evaluation in extranodal nasal-type NK/T-cell lymphoma: a case report.

Liao T, Li L, Fu G, et al.

Frontiers in oncology 2025; (15()):1548785 doi:10.3389/fonc.2025.1548785.

Sinonasal NK/T-cell lymphoma - imaging features overlap with non-neoplastic etiologies.

Brahmbhatt S, Daniel J, Agarwal A, et al.

Emergency radiology 2025; (32(4)):487-493 doi:10.1007/s10140-025-02350-5.

Pathological profile of 1,385 lymphoma cases in Zunyi, China: A classification-based analysis following the WHO 2022 criteria for hematolymphoid tumors.

Ji Q, Su J, Zhang S, et al.

Virchows Archiv : an international journal of pathology 2025; (487(5)):1127-1135 doi:10.1007/s00428-025-04299-9.

EBV-Driven NK/T-Cell Lymphoproliferative Disorders: Clinical Diversity and Molecular Insights.

Luniewski A, Chaudhary S, Goldfarb A, Obiorah IE

Lymphatics 2026; (4(1)) doi:10.3390/lymphatics4010007.

Early diagnosis of extranodal NK/T lymphoma presenting with oral ulcer and lip swelling by metagenomics next-generation sequencing: a case report.

Zhu Z, Kang J, Song M, et al.

BMC oral health 2026; (26(1)).

Necrotic locally advanced nasal NK/T-cell lymphoma: the timely diagnostic challenge.

Garidi R, Aftisse H, Taguelmint N, et al.

Current research in translational medicine 2026; (74(1)):103571 doi:10.1016/j.retram.2026.103571.

[Comparison of Different Staging Systems of Extranodal NK/T Cell Lymphoma and Prognosis Analysis].

Shi FQ, Zhao M, Jia Y, Wang JB

Zhongguo shi yan xue ye xue za zhi 2026; (34(1)):79-85 doi:10.19746/j.cnki.issn.1009-2137.2026.01.011.